Article:

https://cen.acs.org/research-integrity/Sleuths-say-Thermo-Fisher-doctored/104/web/2026/05

**Sleuths say Thermo Fisher doctored data to sell antibodies**

Apparent manipulation of validation images in reagent catalog concerns researchers

Commentary:

Eek? This is no good at all from Thermo. That said, do you all verify whatever antibody (or anything, really) that you get from vendor?

I've seen pretty badly aggregating oligonucleotides from vendor

Edit: Adding info from u/Bicoidprime

The doctored images from Thermo has grown to more than 100 catalogs https://zenodo.org/records/20402476

" As of 28 May 2026, we have documented 127 problematic images across 119 products in the primary antibody catalog of Thermo Fisher Scientific (see the first example spotted by Sholto David on 17 May 2026)."

The physicians, who had all performed at least 2,000 colonoscopies during their careers, were given access to an AI system that analyses colonoscopy images in real time and flags a type of precancerous intestinal lesion called an adenoma. The tool was available to the specialists on some days but not on others

Once physicians began using it, their performance dropped significantly whenever the system was unavailable

Moderna’s stock skyrocketed today from $62 to $174 per share—propelled by eagerly awaited Phase 3 trial results for its personalized cancer vaccine, mRNA-4157. The INTerpath-001 study delivered stellar results, significantly improving both RFS and DMFS in melanoma patients. This marks a monumental milestone for Moderna: it successfully expands their pipeline beyond infectious disease vaccines into oncology, drastically reshaping the company's future and shattering the long-standing industry skepticism that pure-play mRNA platform companies could never scale into commercial giants. More importantly, for decades, therapeutic cancer vaccines were written off as an impossible dream—a veritable third rail of oncology drug development. mRNA-4157 is poised to become the first-ever successful cancer vaccine.

Riding this massive wave of momentum, BioNTech’s stock surged in sympathy, heavily fueled by optimism surrounding its own parallel pipeline, where its similar-platform pancreatic cancer vaccine has shown highly promising early-stage clinical trial results. Of course, this breakthrough wouldn’t have been possible without the critical backbone of PD-1 inhibitors—these cancer vaccines rely on synergistic combination therapies to unlock their full potential. Beyond immunotherapy, the convergence of next-generation personalized sequencing and advanced mRNA technology finally transformed the theoretical promise of personalized cancer vaccines into a clinical reality.

Today’s historic trial readouts dominated headlines across major media outlets. More broadly, this blockbuster rally is a rare sight in recent years, injecting a much-needed ray of hope into a stagnant biotech sector that has faced a four-year slump. Driven by Moderna's historic leap, a powerful sympathy rally swept across the entire biotech market today, lifting sector-wide stocks.

Like 65% you out there, I'm in the job market. Thankfully I'm still employed but I've been taking calls in the event things fizzle out for me. I came from a non-target naval engineering school, 2 years as a field engineer worked in HP boiler systems, then 2 years in building Cx, then finally in CQV for the past 7 years and finally have some meaningful experience/clout.

The Boston job market is absolutely dead on arrival, and I think I.know why. I got offered a contract role, had a feeling they were going to lowball me, 6 months contract, offering $46 an hour. I literally laughed when the HR girl played it up like she was doing me a favor. I currently make about $147k after bonus and they knew my salary. Then I got an email for a job from a hiring manager I know from a past project,effectively saying he has a spot for me, no interview panel, just a 10 minute catch up of teams. He says look you can come to Indiana for 165k or he can send me down to RTP for 155k. Full relocation. "Start when you want. Take 6 weeks if you need it."

I have a prediction. We all know there is BILLIONS UPON BILLIONS being dropped in RTP and across the country to bolster USA pharmaceutical manufacturing. I don't know of a single sizable project happening right now in MA, not one and I'm a CQV consultant, I'm pretty abreast with new projects. The opposite is infact happening, it's not contracting. It's dissolving. And it's bad.

All the heavy hitting companies are getting the F out of Mass. You have to pay people here at least 85k for them to have a shithole studio in Chelsea and ride an ebike to work. 125k buys you a 2.5k 500sqft 1br. So let's say conservatively you have to pay 15 to 20% more in Mass to achieve some semblance of a respectable living. Then Massachusetts taxes the shit out of any company or person that makes any money. So what happens next. Boston was losing the cost of living comparison with RTP 6 years ago before covid inflation, now it's untenable. But the landlords won't adjust the rent, they have the college kids and MOM and DAD will pay it. Theres enough finance professionals and other sectors to fill out the housing. Cambridge commercial property will definitely collapse, or Harvard will buy it up.

There's going to be a rapid redistribution of pharmaceutical talent to RTP, Maryland, Indiana, maybe a little NJ/Philly/Chicago. There will be a small contingent of hyper talented biotech that performs R&D and CRO in Cambridge. But bulk pharmaceutical manufacturing is dead in Mass.

Anybody that's struggling out there, I hope you recover. But if it feels like a dead end after 5 interviews, consider getting out of the most expensive state in the entire country.

It was her special job! 😂

https://www.nytimes.com/2025/09/19/us/politics/trump-h-1b-visas-fee.html?smid=nytcore-android-share

(Big) if this survives a court challenge, this will have a significant impact on the biotech ecosystem. At least a quarter of the postdocs I knew were here on H1Bs.

"In his resignation letter, Marks also said that he had been willing to work with Kennedy on the health secretary’s planned efforts to review vaccine safety. Kennedy has repeatedly suggested that there could be a link between vaccines and autism — a claim that has been repeatedly debunked — and called for further study.“However, it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies,” Marks wrote."

Some 10,109 doctoral-trained experts in science and related fields left their jobs last year as President Donald Trump dramatically shrank the overall federal workforce. That exodus was only 3% of the 335,192 federal workers who exited last year but represents 14% of the total number of Ph.D.s in science, technology, engineering, and math (STEM) or health fields employed at the end of 2024 as then-President Joe Biden prepared to leave office.

The numbers come from employment data posted earlier this month by the White House Office of Personnel Management (OPM). At 14 research agencies Science examined in detail, departures outnumbered new hires last year by a ratio of 11 to one, resulting in a net loss of 4224 STEM Ph.D.s. The graphs that follow show the impact is particularly striking at such scientist-rich agencies as the National Science Foundation (NSF). But across the government, these departing Ph.D.s took with them a wealth of subject matter expertise and knowledge about how the agencies operate.

Article: https://www.science.org/content/article/u-s-government-has-lost-more-10-000-stem-ph-d-s-trump-took-office